Compare QUALCOMM, Inc. (QCOM) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
QUALCOMM, Inc. vs TG Therapeutics Inc — how do they compare? QUALCOMM, Inc. trades at $176.95 (market cap $182.87B), while TG Therapeutics Inc trades at $52.7 (market cap $8.26B). The key difference: QUALCOMM, Inc. is far larger — about 22.1× TG Therapeutics Inc's market cap, and QUALCOMM, Inc. pays a 2.12% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| QCOM | TGTX | |
|---|---|---|
Market Cap | $182.87B | $8.26B |
Sector | Technology | Health |
52-Week High | $251.10 | $59.06 |
52-Week Low | $124.07 | $26.39 |
Enterprise Value | $188.34B | $8.50B |
Dividend Yield | 2.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Qualcomm (QCOM) trades at $175.55, up 3.07% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 22.31% net income margin and 29.27% ROE, though margins face pressure. Analyst consensus is a $228.22 price target with 42.65% buy ratings. Recent news highlights AI and data center growth initiatives amid smartphone market challenges.
The outlook balances AI diversification potential against near-term margin and competitive risks. Investment opportunity lies in data center revenue growth and market share gains, but risks include Nvidia's PC chip entry and handset demand softness. Wall Street remains cautiously optimistic with a hold-heavy rating distribution.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
